Nu Med Plus Stock Performance
| NUMD Stock | USD 0.01 0 10.00% |
The company owns a Beta (Systematic Risk) of -1.92, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Nu Med are expected to decrease by larger amounts. On the other hand, during market turmoil, Nu Med is expected to outperform it. At this point, Nu Med Plus has a negative expected return of -1.39%. Please make sure to verify Nu Med's variance and the relationship between the treynor ratio and price action indicator , to decide if Nu Med Plus performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nu Med Plus has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 188.5 K | |
| Free Cash Flow | -206.8 K |
NUMD |
Nu Med Relative Risk vs. Return Landscape
If you would invest 5.00 in Nu Med Plus on September 23, 2024 and sell it today you would lose (3.74) from holding Nu Med Plus or give up 74.8% of portfolio value over 90 days. Nu Med Plus is currently does not generate positive expected returns and assumes 11.9183% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than NUMD, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nu Med Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nu Med's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Nu Med Plus, and traders can use it to determine the average amount a Nu Med's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1167
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NUMD |
Estimated Market Risk
| 11.92 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nu Med is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nu Med by adding Nu Med to a well-diversified portfolio.
Nu Med Fundamentals Growth
NUMD OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Nu Med, and Nu Med fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NUMD OTC Stock performance.
| Return On Equity | -545.23 | |||
| Return On Asset | -6.62 | |||
| Current Valuation | 1.63 M | |||
| Shares Outstanding | 81.35 M | |||
| Price To Earning | 19.00 X | |||
| Price To Book | 49.86 X | |||
| EBITDA | (808.68 K) | |||
| Cash And Equivalents | 2.54 K | |||
| Total Debt | 2.06 K | |||
| Debt To Equity | 0.04 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (206.83 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 22.16 K | |||
| Retained Earnings | (2.41 M) | |||
| Current Asset | 57.17 K | |||
| Current Liabilities | 490.62 K | |||
About Nu Med Performance
By analyzing Nu Med's fundamental ratios, stakeholders can gain valuable insights into Nu Med's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nu Med has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nu Med has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about Nu Med Plus performance evaluation
Checking the ongoing alerts about Nu Med for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Nu Med Plus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nu Med Plus generated a negative expected return over the last 90 days | |
| Nu Med Plus has high historical volatility and very poor performance | |
| Nu Med Plus has some characteristics of a very speculative penny stock | |
| Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu Med until it has trouble settling it off, either with new capital or with free cash flow. So, Nu Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NUMD to invest in growth at high rates of return. When we think about Nu Med's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations. | |
| Roughly 62.0% of Nu Med outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Dexcom implements GenAI into glucose biosensor devices |
- Analyzing Nu Med's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nu Med's stock is overvalued or undervalued compared to its peers.
- Examining Nu Med's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nu Med's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nu Med's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Nu Med's otc stock. These opinions can provide insight into Nu Med's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NUMD OTC Stock analysis
When running Nu Med's price analysis, check to measure Nu Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Med is operating at the current time. Most of Nu Med's value examination focuses on studying past and present price action to predict the probability of Nu Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Med's price. Additionally, you may evaluate how the addition of Nu Med to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |